Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 2Head & Neck 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 154Stomach Neoplasms 23Neoplasms 18Neoplasm Metastasis 17Esophageal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Cholangiocarcinoma 12Adenocarcinoma 11Breast Neoplasms 9Pancreatic Adenocarcinoma 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Carcinoma, Pancreatic Ductal 7Biliary Tract Neoplasms 7Lung Neoplasms 6Gallbladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Diseases 5Digestive System Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Endocrine Gland Neoplasms 4Digestive System Diseases 4Advanced Pancreatic Cancer 4Rectal Neoplasms 3Neoplasms, Glandular and Epithelial 3Neoplasms by Site 3

Interventions

Gemcitabine 11pembrolizumab 10Oxaliplatin 7Nivolumab 7Irinotecan 7Fluorouracil 7Capecitabine 7durvalumab 6Sorafenib 6Leucovorin 6Cyclophosphamide 6Paclitaxel 5Ipilimumab 5tislelizumab 3poly ICLC 3lenvatinib 3fludarabine 3Sunitinib 3Radiotherapy 3Cisplatin 3Cetuximab 3130-nm albumin-bound paclitaxel 3seocalcitol 2selinexor 2pemigatinib 2futuximab 2fludarabine phosphate 2donafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Albumin-Bound Paclitaxel × Gastrointestinal × Clear all
NCT01431794 2020-01-22

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Terminated
23 enrolled 10 charts
Gastrointestinal

Carcinoma, Pancreatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡